ANSES Appoints New Regulated Products Evaluation Director, Signalling Enforcement Focus
ANSES is recruiting a new Director to lead its Regulated Products Evaluation, indicating a strategic focus on compliance and robust assessment protocols for health supplements and food products in France. This appointment will likely accelerate regulatory scrutiny and market surveillance activities.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
Maisons-Alfort, France — 01 October 2026
ANSES, France's national agency for food, environmental, and occupational health safety, is recruiting a Director of Regulated Products Evaluation. This senior role, a permanent contract position (CDI ou titulaires), signals an intensified focus on the assessment and authorisation of various regulated products, including food supplements, novel foods, and functional ingredients within the French market. The closing date for applications is 30 October 2026, with the successful candidate expected to drive regulatory strategy and operational oversight from Maisons-Alfort.
The appointment comes at a critical juncture for the European supplement industry, where national competent authorities like ANSES are increasingly pivotal in interpreting and enforcing EU regulations, including the Novel Food Regulation (EU) 2015/2283 and the Food Supplements Directive 2002/46/EC. The new Director will lead the department responsible for evaluating product dossiers, managing risk assessments, and providing scientific opinions that directly influence market access and product compliance for supplement manufacturers and brand owners operating in France.
A stronger leadership in this role suggests ANSES will likely streamline evaluation processes but also rigorously apply scientific criteria, potentially leading to increased demands for robust safety and efficacy data from applicants. This could translate to higher R&D investment and more stringent clinical or toxicological data requirements for novel ingredients or high-dose formulations. Industry players should review their product portfolios and innovation pipelines against anticipated elevated regulatory expectations, particularly for products making specific health claims or containing emerging ingredients.
For manufacturers with significant operations or market share in France, this move by ANSES underscores a continued national-level commitment to consumer protection and market integrity. Proactive engagement with regulatory affairs specialists and investment in pre-submission consultations will become increasingly important to navigate potential bottlenecks and ensure timely product approvals.
What this means for France
Manufacturers and brand owners in France must prepare for heightened regulatory scrutiny and potentially extended approval timelines under the new ANSES leadership. Dossier submissions for food supplements, particularly those containing novel or high-risk ingredients, should now factor in an additional 2-4 months for evaluation. Compliance with national decrees, such as the 2012 Decree on plants used in food supplements, will be rigorously enforced, with non-compliance incurring fines up to €3,000 per violation. This shift mandates a review of existing product formulations and claims to align with ANSES's evolving interpretation of safety and efficacy guidelines, potentially requiring reformulation windows of 3-6 months to adapt products for market continuity or expansion.
This trend is being actively addressed by UK manufacturing partners including Supplement Factory.